THIS MONTH IN

Virtual biopsy: Murray and colleagues look at the concept of virtual biopsies and the likelihood that traditional biopsies can be transformed from physical to virtual while still providing comparable or improved diagnostic and prognostic information. Page 511

Kinetic analysis: Pantel and colleagues offer the second in a series of educational overviews, here focusing on applications of PET tracer kinetic analysis in oncology, current and future research and clinical implementations, and the future of kinetic modeling. Page 514

 Preclinical and phantom¹³³La imaging: Nelson and colleagues report on cyclotron production of clinically relevant ¹³³La activities, compare ¹³³La PET phantom imaging with common PET radionuclide imaging, and describe preclinical PET tumor imaging using ¹³³La-PSMA-I&T. Page 584

¹⁸F-FDG PET and myocardial viability: Mhlanga and colleagues develop a practical protocol for intravenous glucose loading/insulin injection before ¹⁸F-FDG administration for PET myocardial viability evaluation in patients with ischemic cardiomyopathy with and without type 2 diabetes......Page 602

Kinetic analysis of pituitary V_{1B} tracer: Naganawa and colleagues characterize in humans the pharmacokinetic and binding profiles of ¹¹C-TASP699, a novel PET radiotracer with high affinity and selectivity for the vasopressin 1B receptor highly expressed in the pituitary. Page 609

Antibody distribution and immunoPET: Sharma and colleagues report on the influence of crystallizable fragment modifications and IgG subclass on in vivo biodistribution of antibodies and potential associated effects on molecular imaging development of novel antibody-based theranostic agents.....Page 629